Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Article
Nature 445, 437-441 (7 January 2007) | doi:10.1038/nature05474;
Open Innovation Challenges
-
Direct Molecular Detection of Proteins and Nucleic Acids
This Challenge is looking for novel approaches to protein and nucleic acid detection. This is an Id...
-
Novel Approaches to Protecting Maize from Insect Damage
The Seeker is looking for novel approaches to protecting maize from insect damage. This Challenge re...
- More Challenges
- Powered by:
nature jobs
Endowed Professorship in Neuroscience
- University of Tennessee Health Science Center
- Memphis, Tennessee, USA
Paleobiologist / Biogeochemist
- University of Cincinnati
- Cincinnati, Ohio, USA
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Oncogenic tyrosine kinases have proved to be promising targets for the development of highly effective anticancer drugs. However, tyrosine kinase inhibitors (TKIs) against the human epidermal growth factor receptor (HER) family show only limited activity against HER2-driven breast cancers, despite effective inhibition of epidermal growth factor receptor (EGFR) and HER2 in vivo.
&
Abstract
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
